A detailed history of ETF Managers Group, LLC transactions in Enanta Pharmaceuticals Inc stock. As of the latest transaction made, ETF Managers Group, LLC holds 7,080 shares of ENTA stock, worth $44,674. This represents 0.01% of its overall portfolio holdings.

Number of Shares
7,080
Previous 5,185 36.55%
Holding current value
$44,674
Previous $241,000 18.67%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Apr 17, 2023

BUY
$38.82 - $54.59 $73,563 - $103,448
1,895 Added 36.55%
7,080 $286,000
Q4 2022

Mar 23, 2023

SELL
$40.77 - $53.73 $37,956 - $50,022
-931 Reduced 15.22%
5,185 $241,000
Q3 2022

Nov 14, 2022

SELL
$48.29 - $71.27 $20,668 - $30,503
-428 Reduced 6.54%
6,116 $317,000
Q2 2022

Aug 15, 2022

BUY
$38.13 - $76.93 $12,087 - $24,386
317 Added 5.09%
6,544 $307,000
Q1 2022

May 13, 2022

BUY
$56.06 - $74.11 $4,709 - $6,225
84 Added 1.37%
6,227 $431,000
Q4 2021

Feb 14, 2022

SELL
$60.19 - $97.37 $74,515 - $120,544
-1,238 Reduced 16.77%
6,143 $458,000
Q3 2021

Nov 15, 2021

BUY
$41.02 - $58.65 $58,412 - $83,517
1,424 Added 23.9%
7,381 $414,000
Q2 2021

Aug 16, 2021

SELL
$43.76 - $53.11 $9,714 - $11,790
-222 Reduced 3.59%
5,957 $261,000
Q1 2021

May 17, 2021

SELL
$41.69 - $54.95 $149,542 - $197,105
-3,587 Reduced 36.73%
6,179 $297,000
Q4 2020

Feb 16, 2021

SELL
$41.16 - $47.47 $60,834 - $70,160
-1,478 Reduced 13.14%
9,766 $406,000
Q3 2020

Nov 16, 2020

BUY
$43.36 - $53.53 $235,184 - $290,346
5,424 Added 93.2%
11,244 $504,000
Q2 2020

Aug 14, 2020

BUY
$46.37 - $57.58 $269,873 - $335,115
5,820 New
5,820 $285,000

Others Institutions Holding ENTA

About ENANTA PHARMACEUTICALS INC


  • Ticker ENTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,724,900
  • Market Cap $131M
  • Description
  • Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...
More about ENTA
Track This Portfolio

Track ETF Managers Group, LLC Portfolio

Follow ETF Managers Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of ETF Managers Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on ETF Managers Group, LLC with notifications on news.